Form 13-F position report

DIFFUSION PHARMACEUTICALS I

Reported by MORGAN STANLEY

CRVO CUSIP 253748305 Manager CIK 0000895421

Reported 0 shares, down 27,400 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2022
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 6 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 8000
2022-03-31 7000
2022-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

3 quarters
Quarterly reported position history for DIFFUSION PHARMACEUTICALS I held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2022 Reduced 0 -27,400 (-100.0%) 0 $0 2022-08-15
Q1 2022 Reduced 27,400 -8 (0.0%) < 0.01% $7,000 2022-05-13
Q4 2021 Added 27,408 +20,005 (270.2%) < 0.01% $8,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

20 managers reported DIFFUSION PHARMACEUTICALS I for Q2 2022.

Managers reporting DIFFUSION PHARMACEUTICALS I in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ADVISOR GROUP HOLDINGS INC Reduced 0 -30,099 0 $0 10 qtrs
TWO SIGMA SECURITIES LLC Reduced 0 -15,457 0 $0 4 qtrs
Raymond James Financial Services Advisors Inc Reduced 0 -20,500 0 $0 8 qtrs
LPL Financial LLC Reduced 0 -73,049 0 $0 2 qtrs
VANGUARD GROUP INC Reduced 0 -3,998,632 0 $0 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -858,408 0 $0 14 qtrs
Yu Fan Reduced 0 -89,848 0 $0 7 qtrs
MORGAN STANLEY This report Reduced 0 -27,400 0 $0 6 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -627 0 $0 13 qtrs
Tower Research Capital LLC TRC Reduced 0 -103 0 $0 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM PAR

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.